Solid Biosciences Inc. advances SGT-212 gene therapy for Friedreich ataxia into human trials

Solid Biosciences Inc. advances SGT-212 gene therapy for Friedreich ataxia into human trials
Solid Biosciences gene therapy trial

Solid Biosciences Inc. is moving forward with SGT-212, a gene therapy designed to treat Friedreich ataxia, as one of the first therapies of its kind to enter human trials.

The therapy stands out for its approach targeting both neuromuscular and cardiac symptoms of the disease using a novel dual administration route. The move demonstrates Solid Biosciences Inc.'s commitment to accelerating treatments for rare genetic conditions, potentially paving the way for more effective solutions in an area of significant unmet medical need. Further updates on trial progress and patient outcomes are awaited as the company pursues this innovative approach.

Solid Biosciences Inc. previously highlighted advancements in precision gene therapy at a major symposium, focusing on new targeting strategies presented by the company. The organization remains active in developing new approaches for rare genetic conditions. These efforts frame the company’s ongoing push to bring SGT-212 to patients.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.